权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of SGLT3 in diabetes-mediated increased renal sodium reabsorption

SGLT3 在糖尿病介导的肾钠重吸收增加中的作用

基本信息

批准号：
8472483
负责人：
NILOOFAR M TABATABAI
金额：
$ 24.11万
依托单位：
MEDICAL COLLEGE OF WISCONSIN
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-06-15 至 2015-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8472483
关键词：
Affinity Age Agonist Amino Acid Sequence Amino Acid Sequence Homology Animal Model Animals Antibodies Apical Binding Blood Pressure Brain C57BL/6 Mouse COS-7 Cell Cadmium Carrier Proteins Cell Line Cell membrane Cells Chronic Colon Confocal Microscopy Custom Data Development Diabetes Mellitus Diabetic Nephropathy Diabetic mouse End stage renal failure Epithelial Cells Exposure to Family Family suidae Fluorescence Fluorescent Antibody Technique Genes Glucose Glucose Transporter Goals Health Human Hyperglycemia Hypertension Immunoblotting In Vitro Intestines Investigation Ion Channel Ions Kidney Knock-out Knowledge Malignant Epithelial Cell Measures Mediating Mediator of activation protein Membrane Protein Traffic Messenger RNA Microscopy Modeling Mouse Strains Mus Muscle Fibers Na(+)-K(+)-Exchanging ATPase Non-Insulin-Dependent Diabetes Mellitus Oocytes Ovary Phlorhizin Physiological Processes Play Property Protein Isoforms Proteins Proximal Kidney Tubules Rattus Renal carcinoma Research Design Risk Factors Role Secondary to Side Small Intestines Sodium Sodium Chloride Techniques Testing Time Tissues United States Water Xenopus laevis Xenopus oocyte absorption base design diabetic diabetic patient glucose analog glucose transport glucose uptake in vivo kidney cell knock-down mouse model non-diabetic novel public health relevance response small hairpin RNA solute sugar uptake young adult

项目摘要

DESCRIPTION (provided by applicant): Diabetic nephropathy is the leading cause of end-stage renal disease in the United States. Hyperglycemia has been recognized as a major risk factor in the development and progression of diabetic nephropathy. Hyperglycemia-induced increase in proximal tubule (PT) Na+ retention has been shown in diabetic patients and in animal models of diabetes. This enhanced Na+ reabsorption may play a role in the development of hypertension, which is an additional contributing factor in the development of diabetic nephropathy and the end stage renal disease. A role for a PT sodium-glucose cotransporter (SGLT) in hyperglycemia-induced increased sodium retention has been suggested but this transporter has not yet been identified. Kidney expresses SGLT1 and SGLT2 on the apical side of the PT cells. These proteins play crucial roles in sodium-dependent uptake of glucose from the glomerular filtrate. SGLT3 mRNA has been found in the human kidney carcinoma cells and in the pig kidney. When over-expressed in Xenopus oocytes, human SGLT3 did not transport glucose but in response to glucose, it mediated inward flux of sodium. Mouse has two genes encoding SGLT3a and 3b and we have shown that their mRNAs were expressed in the kidney and in the cultured kidney cells from mouse. We also showed while mRNA levels of SGLT3s in cultured mouse primary kidney cells exposed to cadmium were several folds higher than in their levels in untreated cells, the sodium-dependent uptake of glucose in Cd-treated cells had decreased supporting that SGLT3 is not a glucose transporter. Based on the above and additional preliminary studies with the potent agonist of SGLT3, deoxynojirimycin (DNJ), we hypothesize that kidney SGLT3 serves as a novel glucose-stimulated Na+ transporter in the PT that may play role in hyperglycemia-induced Na+ retention in diabetes. To test our hypothesis, we propose: (1) To localize the SGLT3 protein in human and mouse kidneys, (2) To determine the role of SGLT3 in glucose-mediated Na+ uptake in PT cells in vitro, (3) To determine the role of SGLT3 in hyperglycemia-mediated PT Na+ reabsorption in vivo. The proposed in vitro and in vivo studies are designed to investigate the role of SGLT3 as a novel glucose-stimulated Na+ transporter that may play role in the enhanced Na+ reabsorption in diabetes.

描述（由申请人提供）：糖尿病肾病是美国终末期肾病的主要原因。高血压已被认为是糖尿病肾病发展和进展的主要危险因素。在糖尿病患者和糖尿病动物模型中已显示高血糖诱导的近端小管（PT）Na+潴留增加。这种增强的Na+重吸收可能在高血压的发展中起作用，高血压是糖尿病肾病和终末期肾病发展的另一个促成因素。PT钠-葡萄糖协同转运蛋白（SGLT）在高血糖诱导的钠潴留增加中的作用已被提出，但该转运蛋白尚未确定。肾脏在PT细胞的顶侧表达SGLT 1和SGLT 2。这些蛋白质在钠依赖性地从肾小球滤液摄取葡萄糖中起关键作用。SGLT 3 mRNA已在人肾癌细胞和猪肾脏中发现。当在非洲爪蟾卵母细胞中过度表达时，人SGLT 3不转运葡萄糖，但响应于葡萄糖，它介导钠的向内流动。小鼠有两个编码SGLT 3a和3b的基因，我们已经证明它们的mRNA在小鼠肾脏和培养的肾细胞中表达。我们还发现，虽然暴露于镉的培养小鼠原代肾细胞中SGLT 3s的mRNA水平比未处理细胞中的水平高出数倍，但镉处理细胞中葡萄糖的钠依赖性摄取降低，这支持SGLT 3不是葡萄糖转运蛋白。基于上述和SGLT 3强效激动剂脱氧野尻霉素（DNJ）的其他初步研究，我们假设肾脏SGLT 3作为PT中的新型葡萄糖刺激Na+转运蛋白，可能在糖尿病高血糖诱导的Na+潴留中发挥作用。为了验证我们的假设，我们提出：（1）在人和小鼠肾脏中定位SGLT 3蛋白，（2）确定SGLT 3在体外葡萄糖介导的PT细胞Na+摄取中的作用，（3）确定SGLT 3在体内高血糖介导的PT Na+重吸收中的作用。拟定的体外和体内研究旨在研究SGLT 3作为一种新型葡萄糖刺激的Na+转运蛋白的作用，该转运蛋白可能在糖尿病Na+重吸收增强中发挥作用。